With 0.62 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.81 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $73.95 whereas the lowest price it dropped to was $72.81. The 52-week range on GMED shows that it touched its highest point at $75.98 and its lowest point at $43.38 during that stretch. It currently has a 1-year price target of $81.58. Beta for the stock currently stands at 1.17.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GMED was down-trending over the past week, with a drop of -1.32%, but this was up by 4.09% over a month. Three-month performance surged to 2.98% while six-month performance rose 43.64%. The stock gained 46.55% in the past year, while it has gained 38.66% so far this year. A look at the trailing 12-month EPS for GMED yields 0.30 with Next year EPS estimates of 3.34. For the next quarter, that number is 0.65. This implies an EPS growth rate of 23.19% for this year and 16.70% for next year. EPS is expected to grow by 12.74% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -7.04%.
Float and Shares Shorts:
At present, 113.91 million GMED shares are outstanding with a float of 112.15 million shares on hand for trading. On 2024-09-30, short shares totaled 3.41 million, which was 252.0 higher than short shares on 1724976000. In addition to Mr. David C. Paul as the firm’s Co-Founder & Executive Chairman, Mr. Daniel T. Scavilla serves as its President, CEO & Director.
Institutional Ownership:
Through their ownership of 1.0305899 of GMED’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, GMED reported revenue of $629691000.0 and operating income of $64125000.0. The EBITDA in the recently reported quarter was $142919000.0 and diluted EPS was $0.23.
